The FDA accelerated the approval of the RAF inhibitor Tovorafenib (Ojemda) in April 2024 for the treatment of patients with recurrent/refractory low-grade glioma in children carrying BRAF gene variants. THE FIREFLY-1 study SHOWED A TOTAL REMISSION RATE OF 51% AND A MEDIAN REMISSION DURATION OF 13.8 MONTHS, PROVIDING THE FIRST BRAF TARGETED TREATMENT OPTION FOR CHILDREN WITH BRAIN TUMORS. The United Cancer Centre of Hong Kong provides professional child cancer consultation.